ADMA Biologics
ADMAADMA · Stock Price
Historical price data
Overview
ADMA Biologics has established a unique and defensible position as the only fully integrated, U.S.-based producer of plasma-derived immunoglobulins, controlling the entire process from plasma collection to commercial manufacturing. The company's mission is to serve underserved patient populations with primary and secondary immunodeficiencies through its proprietary plasma screening and manufacturing technologies. Its strategic achievements include building a network of plasma collection centers (ADMA BioCenters), securing FDA approval for three products (ASCENIV, BIVIGAM, Nabi-HB), and achieving profitability, driven by its vertically integrated model which ensures supply reliability and favorable unit economics.
Technology Platform
A proprietary microneutralization assay for screening high-titer plasma donors, coupled with a fully vertically integrated manufacturing platform encompassing plasma collection, fractionation, purification, and fill/finish.
Pipeline
7| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Asceniv™ | Primary Immune Deficiency | Approved | |
| Bivigam | Humoral Immune Response | Approved | |
| Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] | Primary Immune Deficiency Disorders (PIDD) | Phase 3 | |
| RI-002 | Primary Immune Deficiency Disorder | Phase 3 | |
| RI-001 + RI-001 + RI-001 | Upper Respiratory Tract Infection | Phase 2 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
ADMA competes with global plasma giants like Takeda, Grifols, CSL, and Octapharma. Its differentiation lies in its complete U.S. vertical integration, which ensures supply chain control and cost advantages, and its proprietary hyperimmune product (ASCENIV), which offers clinical differentiation for a subset of patients with recurrent infections.